Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 27, 2009 (Three and Nine Months)
Business Overview: Illumina is a leading developer of integrated systems for large-scale genetic analysis, serving sequencing, genotyping, and gene expression markets. The company operates primarily in one segment (Life Sciences) as the Diagnostics Business Unit has not yet met reporting thresholds.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sept 27, 2009 |
3 Months Ended Sept 28, 2008 |
9 Months Ended Sept 27, 2009 |
9 Months Ended Sept 28, 2008 |
|---|---|---|---|---|
| Total Revenue | $158,360 | $150,260 | $485,760 | $412,298 |
| Net Income (Loss) | $17,077 | $(10,078) | $60,576 | $13,324 |
| Diluted EPS | $0.12 | $(0.08) | $0.44 | $0.10 |
| Operating Cash Flow | N/A | N/A | $113,168 | $37,765 |
| Cash & Equivalents | $238,528 | N/A | N/A | N/A |
| Total Investments | $576,852 | N/A | N/A | N/A |
| Long-Term Debt (Current Portion) | $284,708 | $276,889 | N/A | N/A |
Note: The company reported a net income of $17.1M for the quarter, a significant improvement from a net loss of $10.1M in the prior year quarter. Operating cash flow for the nine-month period increased to $113.2M from $37.8M.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5% year-over-year for the quarter and 18% for the nine-month period. This was driven by a 30% increase in instrument sales (Genome Analyzer systems) and a 22% increase in sequencing consumables.
- Profitability: The company returned to profitability, reporting net income of $17.1M for the quarter compared to a loss of $10.1M in the same period last year. Operating income improved from $1.5M to $29.3M.
- Expense Increases: Research and Development (R&D) expenses rose 25% for the quarter and 40% for the nine-month period, primarily due to personnel growth and stock-based compensation. Selling, General, and Administrative (SG&A) expenses also increased.
- Accounting Changes: The company adopted new authoritative guidance for convertible debt instruments (effective Dec 29, 2008) and revenue recognition for multiple deliverables (effective Sept 27, 2009). These changes resulted in retroactive adjustments to prior period financials and increased interest expense due to the amortization of debt discounts.
Outlook, Risks, and Unusual Items
- Quality Issue & Shipping Hold: In late September 2009, the company identified a quality issue with paired-end cluster kits, resulting in higher error rates for some customers. Illumina elected to hold all shipments of these kits to manufacture and test new lots. Management expects to clear the backlog in early November but anticipates a negative impact on Q4 2009 revenue.
- Outlook: Management expects continued strong demand for next-generation sequencing. However, visibility into future revenue is limited due to the concentration of order recognition in the final weeks of the quarter. Operating costs are expected to increase to support business growth.
- Liquidity: As of September 27, 2009, the company held $815.4 million in cash, cash equivalents, and investments. This includes $55.5 million in illiquid auction rate securities, for which the company has a settlement agreement with UBS allowing repurchase at par value between June 2010 and July 2012.
- Risks: Key risks include dependence on third-party suppliers for components, potential regulatory hurdles for molecular diagnostic products (FDA approval), and the impact of funding levels from government grants (e.g., American Recovery and Reinvestment Act).
Investor Verification Checklist
- Quality Resolution: Verify the timeline for clearing the paired-end cluster kit shipping backlog and the extent of the revenue impact on Q4 2009.
- Debt Conversion: Monitor the status of the $400 million convertible senior notes, which are convertible through December 31, 2009, and the associated dilution risks.
- Auction Rate Securities: Confirm the liquidity status of the $55.5 million in auction rate securities and the enforceability of the UBS settlement agreement.
- Regulatory Status: Track progress on FDA clearance for any products transitioning from "Research Use Only" to diagnostic applications.
- Expense Management: Assess whether the significant increase in R&D and SG&A expenses (driven by personnel and stock compensation) is sustainable relative to revenue growth.